Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
May 22, 2025
May 22, 2025
LONDON, England, May 22 [Category: BizPharmaceuticals] -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
* Nucala is the only approved biologic studied in a wide COPD population with an eosinophilic phenotype characterised by blood eosinophil count (BEC) starting at 150 cells/mL
* . . .
* * *
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
* Nucala is the only approved biologic studied in a wide COPD population with an eosinophilic phenotype characterised by blood eosinophil count (BEC) starting at 150 cells/mL
* . . .